Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Australian Manufacturing Week 2026 to make Brisbane debut
Australia’s leading advanced manufacturing showcase, Australian Manufacturing Week (AMW), is set to return in 2026, marking its first-ever event in Brisbane.
